Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24811024 | 0.81 | LMNA (0.39) | FAAHDNM1KMT2AMEN1MAPK1 | |
| SCHEMBL16293640 | 0.80 | DNM1 (0.59) | FAAHCAPN1DNM1KMT2ATSHR | |
| SCHEMBL24477430 | 0.79 | FAAH (0.53) | FAAHDNM1KMT2AMEN1MAPK1 | |
| SCHEMBL23191849 | 0.79 | DNM1 (0.60) | FAAHDNM1KMT2AMEN1MAPK1 | |
| SCHEMBL9618659 | 0.75 | FAAH (0.81) | FAAHDNM1KMT2AMEN1MAPK1 | |
| SCHEMBL12346213 | 0.75 | FAAH (0.73) | FAAHDNM1KMT2AMEN1TSHR | |
| SCHEMBL5508427 | 0.75 | TDP1 (0.36) | CHRNB2CHRNB4CHRNA4ALDH1A1 | |
| SCHEMBL26557081 | 0.74 | DNM1 (0.50) | FAAHDNM1HPGDALDH1A1 | |
| SCHEMBL26724577 | 0.74 | DNM1 (0.46) | FAAHDNM1KMT2AMEN1MCL1 | |
| SCHEMBL9883738 | 0.74 | LMNA (0.43) | KMT2AMEN1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2021102332-A1 | TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | TGFBR2, ACVR2A, SMAD2 | FAAH 3393/4885CAPN1 2082/4885DNM1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.